On a disclosed basis, revenue fell from KRW 1.07 trillion in 2022 to KRW 356.6 billion in 2023 (down 66.6% year on year), KRW 110.1 billion in 2024 (down 69.1%) and KRW 29.3 billion in 2025 (down 73.3%).
Revenue declined for three consecutive years from 2023 to 2025; 2022 was the largest year and 2025 the smallest within 2022 to 2025. Press reports say the company attributed the 2025 decline mainly to lower sales as COVID-19 testing demand fell.
Operating profit dropped from KRW 485 billion in 2022 to KRW 22.1 billion in 2023 (down 95.4%), and the company swung to an operating loss of KRW 4.14 billion in 2024. The operating loss widened to KRW 59.5 billion in 2025, the second consecutive loss year.
Operating margin moved from 45.4% in 2022 to 6.2% in 2023, -3.8% in 2024 and -202.7% in 2025, suggesting cost adjustments did not keep pace with the sales decline.
Net profit attributable to controlling shareholders went from KRW 358.3 billion in 2022 to a KRW 3.25 billion loss in 2023, a KRW 340 million loss in 2024 and a KRW 77.1 billion loss in 2025.
Net loss including non-controlling interests was KRW 78 billion in 2025, a different figure from the controlling-shareholder loss.
Quarterly revenue went from KRW 3.36 billion in Q3 2025 to KRW 4.75 billion in Q4 2025 (up 41.2% quarter on quarter), KRW 4.91 billion in Q1 2026 (up 3.5%), KRW 8.58 billion in Q2 2026 (up 74.7%) and KRW 12.7 billion in Q3 2026 (up 47.8%, and up 277.5% year on year), a four-quarter run of increases.
Operating losses over the same period were KRW 13.1 billion, KRW 20.7 billion, KRW 10.3 billion, KRW 21.3 billion and KRW 7.09 billion, which is five straight loss quarters, with the Q3 2026 loss narrower than both the prior quarter and the year-earlier quarter.
The net loss attributable to controlling shareholders over the last four quarters totals KRW 100 billion, and the Q3 2026 figure was KRW 8.27 billion. Operating cash flow was KRW -27.2 billion in 2025, after a KRW 18.1 billion inflow in 2024.